NMPA grants priority review to Hengrui’s Trastuzumab Rezetecan NDA for 1L HER2-positive breast cancer

SEC recommends approval for additional indication of AstraZeneca’s anti-cancer drug

Alphamab oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was approved...

CSPC Pharmaceutical Group has initiated phase 1/2 clinical trial of SYS6043 for the Solid tumor...

Sino biopharmaceutical enters strategic oncology partnership with Boehringer Ingelheim valued at up to US$7 billion

Telix Joins Thera4Care with TLX400-Tx to accelerate translation of next generation FAP-targeting theranostics